{"id":"W4281670144","doi":"10.1200/jco.2022.40.16_suppl.7545","title":"Favezelimab (anti–LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti–PD-1 treatment: An open-label phase 1/2 study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Refractory (planetary science); Internal medicine; Cohort; Oncology; Clinical endpoint; Neutropenia; Gastroenterology; Cancer; Clinical trial; Toxicity; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001018089,0.0009330604,0.001419068,0.0003706416,0.0003406755,0.0007115581,0.0005225671,0.0006960953,0.002318186],"category_scores_gemma":[0.0005281093,0.0005195106,0.001071906,0.0003084689,0.0005311351,0.0007790524,0.0002934456,0.001681254,0.0005910255],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001093806,"about_ca_system_score_gemma":0.001266236,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001178017,"about_ca_topic_score_gemma":0.003753817,"domain_scores_codex":[0.999745,0.00009864214,0.00001491773,0.00005309189,0.00002362202,0.00006477481],"domain_scores_gemma":[0.9996495,0.00004861505,0.00006389889,0.00002627893,0.00002040601,0.0001913113],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7345802,0.08207453,0.01917373,0.001102383,0.002295297,0.0004284961,0.0004647482,0.001912922,0.03309766,0.0001946708,0.00252163,0.1221538],"study_design_scores_gemma":[0.4105036,0.5582904,0.02487748,0.00005175499,0.0007247082,0.0002954295,0.00009008454,0.0007537954,0.00165793,0.000133528,0.002595437,0.00002591388],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956189,0.001607825,0.0002199067,0.000142702,0.00006435134,0.001274905,0.0003213685,0.00003782909,0.0007120936],"genre_scores_gemma":[0.9955664,0.001057618,0.0005939746,0.0004135764,0.0001097386,0.0009421743,0.0005049342,0.000008561197,0.0008030063],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002318186,"threshold_uncertainty_score":0.00793612,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1242447276767621,"score_gpt":0.4606070160764876,"score_spread":0.3363622883997255,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}